Darovasertib's NDA submission for 1L HLA-A2-neg mUM tests whether a Phase 2b/3 PFS win translates to FDA approval in an ultra-orphan indication with no prior systemic standard of care

Bull

A complete, accepted NDA submission under RTOR — followed by FDA granting priority review and ultimately accelerated or standard approval — would establish darovasertib plus crizotinib as the first approved systemic therapy for HLA-A*02:01-negative metastatic uveal melanoma, a population of roughly 3,000–4,000 new patients annually in the U.S. with no meaningful therapeutic alternative. Given the magnitude of the PFS benefit (HR 0.42, p<0.0001) and 37% ORR versus 6% for control, the data package is compelling for an ultra-orphan indication, and approval would create an immediate commercial opportunity with favorable pricing power and a clear path to label expansion via OptimUM-01 in the HLA-A2-positive population.

Bear

The most likely failure modes are an FDA Complete Response Letter citing insufficient overall survival data or durability of response in a small trial, a request for a confirmatory randomized trial before full approval is granted, or a clinical hold or manufacturing deficiency delaying the submission beyond H2 2026 and eroding first-mover advantage. Additionally, the modest median PFS of 6.9 months — while statistically transformative versus control — may prompt FDA to require post-marketing OS confirmation as a condition of accelerated approval, introducing regulatory uncertainty and limiting near-term commercial momentum.